Search

Your search keyword '"Oosting, Sjoukje F"' showing total 211 results
Start Over Author "Oosting, Sjoukje F" Language english
211 results on '"Oosting, Sjoukje F"'

3. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Author

Rischin, Danny, Hughes, Brett GM, Gao, Bo, McGrath, Margaret, Greil, Richard, Thurnher, Dietmar, Fuereder, Thorsten, Burian, Martin, Rottey, Sylvie, Machiels, Jean-Pascal, Clement, Paul M, Henry, Stéphanie, Deheneffe, Stéphanie, Vasconcelos Alves, Gustavo, Lima, Iane Pinto Figueiredo, Mourão Dias, Josiane, De Marchi, Pedro Rafael Martins, Mak, Milena Perez, Pereira de Santana Gomes, Andrea Juliana, Oliveira de Castro Junior, Dalvaro, Motta, Tatiane Cardoso, Agostinho Padoan, Monica Luciana, Victorina, Ana Paula, de Azevedo, Sergio Jobim, Siu, Lillian L, Brule, Stephanie, Hilton, John, Wang, Chang Shu, Bouganim, Nathaniel, Webster, Marc, Walker, John, Chua, Neil, Zambrano, Angela Regina, Quiroga Echeverri, Alicia, Niño Gomez, Oscar Mauricio, Ortiz, Carlos Alberto, Rojas, Luis, Cardona Zorilla, Andrés, Urrego Meléndez, Olga Marcela, Holečková, Petra Beran, Melichar, Bohuslav, Cvek, Jakub, Prausová, Jana, Vošmik, Milan, Delord, Jean-Pierre, Zasadny, Xavier, Geoffrois, Lionnel, Tao, Yungan, Pointreau, Yoann, Fietkau, Rainer, Haderlein, Marlen, Mueller, Andreas H, Schroeder, Ursula, Wollenberg, Barbara, Laban, Simon, Ivanyi, Philipp, Gruenwald, Viktor, Schafhausen, Philippe, Gutfeld, Orit, Gluck, Iris, Popovtzer, Aron, Meirovitz, Amichay, Billan, Salem, Brenner, Baruch, Limon, Dror, Licitra, Lisa, Perri, Francesco, Caponigro, Francesco, Violati, Martina, Ferrari, Daris, Nole, Franco, Bertolini, Federica, Livi, Lorenzo, Ghi, Maria Grazia, Imarisio, Ilaria, Tahara, Makoto, Homma, Akihiro, Ueda, Tsutomu, Asada, Yukinori, Yamazaki, Tomoko, Matsumoto, Koji, Fujii, Takashi, Ikeda, Sadakatsu, Takahashi, Shunji, Kinoshita, Takashi, Sasaki, Keita, Tsuji, Akihito, Ahn, Myung-Ju, Cho, Byoung Chul, Lee, Keun-Wook, Lee, Ki Hyeong, Choi, Moon Ki, Yun, Hwan Jung, Hendriks, Mathijs P, Oosting, Sjoukje F, Buter, Jan, Van Meerten, Esther, Graham, Jonathan, Kawecki, Andrzej, Debicka, Izabella, Maciejczyk, Adam, Pysz, Maciej, Filarska, Dorota, Hetnał, Marcin, Koralewski, Piotr, Wygoda, Andrzej, Składowski, Krzysztof, Talerczyk, Małgorzata, Berrocal Jaime, Alfonso, Pérez Segura, Pedro, Braña García, Irene, Basté Rotllan, Neus, Mesía Nin, Ricard, Taberna Sanz, Miren, Iglesias Docampo, Lara, Soria Rivas, Ainara, Rueda Domínguez, Antonio, Trigo Pérez, José Manuel, Hong, Ruey-Long, Li, Shau-Hsuan, Wang, Hung-Ming, Yen, Chia-Jui, Yang, Muh-Hwa, Chang, Yi-Fang, Liu, Yi-Chun, Lin, Jin-Ching, Ekenel, Meltem, Harputluoğlu, Hakan, Aksoy, Sercan, Özyilkan, Özgür, Bılıcı, Ahmet, Şendur, Mehmet Alı Nahıt, Arslan, Cagatay, Harrington, Kevin, Ramkumar, Shanmugasundaram, Gujral, Dorothy, Stewart, Simon, Powell, Melanie, Sibtain, Amen, Roques, Tom, Yip, Kent, Mirza, Arafat, Sivaramalingam, Muthiah, Belman, Neil D, Agarwala, Sanjiv, Anderson, Ian, Patel, Arpan, Maggiore, Ronald, Baumgart, Megan, Burtness, Barbara, Fidler, Mary Jo, Kaur, Varinder, Gaughan, Elizabeth, Worden, Francis, Rodriguez, Cristina P, Sukari, Ammar, Wong, Deborah, Yom, Sue, Walsh, William V, Fiorillo, Joseph A, Yorio, Jeffrey T, Obara, Grzegorz S, Alves, Gustavo, Hughes, Brett G M, Mesía, Ricard, Taberna, Miren, Waldron, John N, Simon, Christian, Grégoire, Vincent, Harrington, Kevin J, Swaby, Ramona F, Zhang, Yayan, Gumuscu, Burak, and Bidadi, Behzad

Published
2024
Full Text
View/download PDF

5. The PRO-RCC study: a long-term PROspective Renal Cell Carcinoma cohort in the Netherlands, providing an infrastructure for ‘Trial within Cohorts’ study designs

Author

Yildirim, Hilin, Widdershoven, Christiaan V, Aarts, Maureen JB, Bex, Axel, Bloemendal, Haiko J, Bochove-Overgaauw, Deirdre M, Hamberg, Paul, Herbschleb, Karin H, van der Hulle, Tom, Lagerveld, Brunolf W, van Oijen, Martijn GH, Oosting, Sjoukje F, van Thienen, Johannes V, van der Veldt, Astrid AM, Westgeest, Hans M, Zeijdner, Evelijn E, Aben, Katja KH, van den Hurk, Corina, Zondervan, Patricia J, and Bins, Adriaan D

Published
2023
Full Text
View/download PDF

6. Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial

Author

Kist de Ruijter, Laura, van de Donk, Pim P., Hooiveld-Noeken, Jahlisa S., Giesen, Danique, Elias, Sjoerd G., Lub-de Hooge, Marjolijn N., Oosting, Sjoukje F., Jalving, Mathilde, Timens, Wim, Brouwers, Adrienne H., Kwee, Thomas C., Gietema, Jourik A., Fehrmann, Rudolf S. N., Fine, Bernard M., Sanabria Bohórquez, Sandra M., Yadav, Mahesh, Koeppen, Hartmut, Jing, Jing, Guelman, Sebastian, Lin, Mark T., Mamounas, Michael J., Eastham, Jeffrey Ryan, Kimes, Patrick K., Williams, Simon P., Ungewickell, Alexander, de Groot, Derk J. A., and de Vries, Elisabeth G. E.

Published
2022
Full Text
View/download PDF

7. mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapy.

Author

Gangaev, Anastasia, van Sleen, Yannick, Brandhorst, Nicole, Hoefakker, Kelly, Prajapati, Bimal, Singh, Amrita, Boerma, Annemarie, van der Heiden, Marieke, Oosting, Sjoukje F., van der Veldt, Astrid A. M., Hiltermann, T. Jeroen N., GeurtsvanKessel, Corine H., Dingemans, Anne-Marie C., Smit, Egbert F., de Vries, Elisabeth G. E., Haanen, John B. A. G., Kvistborg, Pia, and van Baarle, Debbie

Subjects
T cells, CANCER chemotherapy, COVID-19 vaccines, CANCER cells, FLOW cytometry
Abstract

Introduction: Research has confirmed the safety and comparable seroconversion rates following SARS-CoV-2 vaccination in patients with solid cancers. However, the impact of cancer treatment on vaccine-induced T cell responses remains poorly understood. Methods: In this study, we expand on previous findings within the VOICE trial by evaluating the functional and phenotypic composition of mRNA-1273-induced T cell responses in patients with solid tumors undergoing immunotherapy, chemotherapy, or both, compared to individuals without cancer. We conducted an ELISpot analysis on 386 participants to assess spike-specific T cell responses 28 days after full vaccination. Further in-depth characterization of using flow cytometry was performed on a subset of 63 participants to analyze the functional phenotype and differentiation state of spike-specific T cell responses. Results: ELISpot analysis showed robust induction of spike-specific T cell responses across all treatment groups, with response rates ranging from 75% to 80%. Flow cytometry analysis revealed a distinctive cytokine production pattern across cohorts, with CD4 T cells producing IFNγ, TNF, and IL-2, and CD8 T cells producing IFNγ, TNF, and CCL4. Variations were observed in the proportion of monofunctional CD4 T cells producing TNF, particularly higher in individuals without cancer and patients treated with chemotherapy alone, while those treated with immunotherapy or chemoimmunotherapy predominantly produced IFNγ. Despite these differences, polyfunctional spike-specific memory CD4 and CD8 T cell responses were comparable across cohorts. Notably, immunotherapy-treated patients exhibited an expansion of spike-specific CD4 T cells with a terminally differentiated effector memory phenotype. Discussion: These findings demonstrate that systemic treatment in patients with solid tumors does not compromise the quality of polyfunctional mRNA-1273-induced T cell responses. This underscores the importance of COVID-19 vaccination in patients with solid cancers undergoing systemic treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Considerable interlaboratory variation in PD‐L1 positivity for head and neck squamous cell carcinoma in the Netherlands— A nationwide evaluation study.

Author

Hempenius, Maaike Anna, Koomen, Bregje M, Deckers, Ivette A G, Oosting, Sjoukje F, Willems, Stefan M, and van der Vegt, Bert

Subjects
SQUAMOUS cell carcinoma, PROGRAMMED death-ligand 1, IMMUNE checkpoint inhibitors, HOSPITAL central service departments, CONFIDENCE intervals, OPTIMISM
Abstract

Aims: Patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) are eligible for first‐line immune checkpoint inhibition if their tumour is positive for programmed death ligand 1 (PD‐L1) determined by the combined positive score (CPS). This nationwide study, using real‐world data, investigated the developing PD‐L1 testing landscape in the first 3 years after introduction of the test in HNSCC and examined interlaboratory variation in PD‐L1 positivity rates. Methods: Pathology reports of HNSCC patients mentioning PD‐L1 were extracted from the Dutch Pathology Registry (Palga). Tumour and PD‐L1 testing characteristics were analysed per year and interlaboratory variation in PD‐L1 positivity rates was assessed using funnel plots with 95% confidence limits around the overall mean. Results: A total of 817 PD‐L1 tests were reported in 702 patients among 19 laboratories; 85.2% of the tests on histological material were stated to be positive. The national PD‐L1 positivity rate differed significantly per year during the study period (79.7–89.9%). The use of the recommended 22C3 antibody increased from 59.9 to 74.3%. A total of 673 PD‐L1 tests on histological material from 12 laboratories were analysed to investigate interlaboratory variation. Four (33%) deviated significantly from the national mean of PD‐L1‐positive cases using CPS ≥ 1 cut‐off, while two (17%) deviated significantly for CPS ≥ 20 cut‐off. Conclusion: In the first 3 years of PD‐L1 assessment in HNSCC, the testing landscape became more uniform. However, interlaboratory variation in PD‐L1 positivity rates between Dutch laboratories was substantial. This implies that there is a need for further test standardisation to reduce this variation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial

Author

Oosting, Sjoukje F, van der Veldt, Astrid A M, GeurtsvanKessel, Corine H, Fehrmann, Rudolf S N, van Binnendijk, Rob S, Dingemans, Anne-Marie C, Smit, Egbert F, Hiltermann, T Jeroen N, den Hartog, Gerco, Jalving, Mathilda, Westphal, Tatjana T, Bhattacharya, Arkajyoti, van der Heiden, Marieke, Rimmelzwaan, Guus F, Kvistborg, Pia, Blank, Christian U, Koopmans, Marion P G, Huckriede, Anke L W, van Els, Cecile A C M, Rots, Nynke Y, van Baarle, Debbie, Haanen, John B A G, and de Vries, Elisabeth G E

Published
2021
Full Text
View/download PDF

11. Oncological and functional outcomes in T3 and T4 laryngeal cancer patients: choice for larynx preservation or total laryngectomy based on expected laryngeal function.

Author

Nobacht, Arman, Meijer, Tineke W H, Oosting, Sjoukje F, van der Vegt, Bert, Wedman, Jan, Halmos, György B, and Plaat, Boudewijn E C

Subjects
LARYNGEAL tumors, TREATMENT effectiveness, FUNCTIONAL status, TUMOR grading, DESCRIPTIVE statistics, CHEMORADIOTHERAPY, LARYNGECTOMY, SURVIVAL analysis (Biometry), PROGRESSION-free survival, OVERALL survival, EVALUATION
Abstract

Objective: To determine oncological and functional outcomes in patients with T3 and T4 laryngeal carcinoma, in which choice of treatment was based on expected laryngeal function and not T classification. Methods: Oncological outcomes (disease-specific survival and overall survival) as well as functional outcomes (larynx preservation and functional larynx preservation) were analysed. Results: In 130 T3 and 59 T4 patients, there was no difference in disease-specific survival or overall survival rates after radiotherapy (RT) (107 patients), chemoradiotherapy (36 patients) and total laryngectomy (46 patients). The five-year disease-specific survival rates were 83 per cent after RT, 78 per cent after chemoradiotherapy and 69 per cent after total laryngectomy, whereas overall survival rates were 62, 54 and 60 per cent, respectively. Five-year larynx preservation and functional larynx preservation rates were comparable for RT (79 and 66 per cent, respectively) and chemoradiotherapy (86 and 62 per cent, respectively). Conclusion: There is no difference in oncological outcome after (chemo)radiotherapy or total laryngectomy in T3 and T4 laryngeal carcinoma patients whose choice of treatment was based on expected laryngeal function. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Vascular aging in long-term survivors of testicular cancer more than 20 years after treatment with cisplatin-based chemotherapy

Author

Stelwagen, Johannes, Lubberts, Sjoukje, Steggink, Lars C., Steursma, Gerrie, Kruyt, Lara M., Donkerbroek, Jan Willem, van Roon, Arie M., van Gessel, Anne I., van de Zande, Saskia C., Meijer, Coby, Gräfin zu Eulenburg, Christine H., Oosting, Sjoukje F., Nuver, Janine, Walenkamp, Annemiek M. E., Jan de Jong, Igle, Lefrandt, Joop D., and Gietema, Jourik A.

Published
2020
Full Text
View/download PDF

13. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Author

Motzer, Robert J, Rini, Brian I, McDermott, David F, Arén Frontera, Osvaldo, Hammers, Hans J, Carducci, Michael A, Salman, Pamela, Escudier, Bernard, Beuselinck, Benoit, Amin, Asim, Porta, Camillo, George, Saby, Neiman, Victoria, Bracarda, Sergio, Tykodi, Scott S, Barthélémy, Philippe, Leibowitz-Amit, Raya, Plimack, Elizabeth R, Oosting, Sjoukje F, Redman, Bruce, Melichar, Bohuslav, Powles, Thomas, Nathan, Paul, Oudard, Stéphane, Pook, David, Choueiri, Toni K, Donskov, Frede, Grimm, Marc-Oliver, Gurney, Howard, Heng, Daniel Y C, Kollmannsberger, Christian K, Harrison, Michael R, Tomita, Yoshihiko, Duran, Ignacio, Grünwald, Viktor, McHenry, M Brent, Mekan, Sabeen, and Tannir, Nizar M

Published
2019
Full Text
View/download PDF

18. .sup.89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

Author

Bensch, Frederike, van der Veen, Elly L., Lub-de Hooge, Marjolijn N., Jorritsma-Smit, Annelies, Boellaard, Ronald, Kok, Iris C., and Oosting, Sjoukje F.

Subjects
Positron emission tomography -- Usage, Apoptosis -- Analysis, Cancer diagnosis -- Research, Tracers (Biology) -- Analysis, Atezolizumab -- Analysis, Cancer -- Care and treatment, Immunohistochemistry -- Research, Medical research, Biochemistry, Zirconium, Public relations executives, Biological markers, Tomography, Tumors, Medical imaging equipment, Cell death, Antibodies, RNA, Immunotherapy, Biological sciences, Health
Abstract

Programmed cell death protein-1/ligand-1 (PD-1/PD-L1) blockade is effective in a subset of patients with several tumor types, but predicting patient benefit using approved diagnostics is inexact, as some patients with PD-L1-negative tumors also show clinical benefit.sup.1,2. Moreover, all biopsy-based tests are subject to the errors and limitations of invasive tissue collection.sup.3-11. Preclinical studies of positron-emission tomography (PET) imaging with antibodies to PD-L1 suggested that this imaging method might be an approach to selecting patients.sup.12,13. Such a technique, however, requires substantial clinical development and validation. Here we present the initial results from a first-in-human study to assess the feasibility of imaging with zirconium-89-labeled atezolizumab (anti-PD-L1), including biodistribution, and secondly test its potential to predict response to PD-L1 blockade (ClinicalTrials.gov identifiers NCT02453984 and NCT02478099). We imaged 22 patients across three tumor types before the start of atezolizumab therapy. The PET signal, a function of tracer exposure and target expression, was high in lymphoid tissues and at sites of inflammation. In tumors, uptake was generally high but heterogeneous, varying within and among lesions, patients, and tumor types. Intriguingly, clinical responses in our patients were better correlated with pretreatment PET signal than with immunohistochemistry- or RNA-sequencing-based predictive biomarkers, encouraging further development of molecular PET imaging for assessment of PD-L1 status and clinical response prediction. Initial results from a first-in-human study show that PET imaging with PD-L1 antibodies outperforms immunohistochemistry- or RNA-sequencing-based biomarkers for prediction of clinical response to immunotherapy., Author(s): Frederike Bensch [sup.1] , Elly L. van der Veen [sup.1] , Marjolijn N. Lub-de Hooge [sup.2] [sup.3] , Annelies Jorritsma-Smit [sup.2] , Ronald Boellaard [sup.3] , Iris C. Kok [...]

Published
2018
Full Text
View/download PDF

19. Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma

Author

Verhoeff, Sarah R., van Es, Suzanne C., Boon, Eline, van Helden, Erik, Angus, Lindsay, Elias, Sjoerd G., Oosting, Sjoukje F., Aarntzen, Erik H., Brouwers, Adrienne H., Kwee, Thomas C., Heskamp, Sandra, Hoekstra, Otto S., Verheul, Henk, van der Veldt, Astrid A. M., de Vries, Elisabeth G. E., Boerman, Otto C., van der Graaf, Winette T. A., Oyen, Wim J. G., and van Herpen, Carla M. L.

Published
2019
Full Text
View/download PDF

21. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

Author

Bensch, Frederike, van der Veen, Elly L., Lub-de Hooge, Marjolijn N., Jorritsma-Smit, Annelies, Boellaard, Ronald, Kok, Iris C., Oosting, Sjoukje F., Schröder, Carolina P., Hiltermann, T. Jeroen N., van der Wekken, Anthonie J., Groen, Harry J. M., Kwee, Thomas C., Elias, Sjoerd G., Gietema, Jourik A., Bohorquez, Sandra Sanabria, de Crespigny, Alex, Williams, Simon-Peter, Mancao, Christoph, Brouwers, Adrienne H., Fine, Bernard M., and de Vries, Elisabeth G. E.

Published
2018
Full Text
View/download PDF

22. COVID-19 vaccination: the VOICE for patients with cancer

Author

van der Veldt, Astrid A. M., Oosting, Sjoukje F., Dingemans, Anne-Marie C., Fehrmann, Rudolf S. N., GeurtsvanKessel, Corine, Jalving, Mathilde, Rimmelzwaan, Guus F., Kvistborg, Pia, Blank, Christian U., Smit, Egbert F., Lemmens, Valery E. E. P., Hiltermann, T. Jeroen N., Koopmans, Marion P. G., Huckriede, Anke L. W., Rots, Nynke Y., van Els, Cecile A. C. M., van Baarle, Debbie, Haanen, John B. A. G., and de Vries, Elisabeth G. E.

Published
2021
Full Text
View/download PDF

27. Swallowing sparing intensity modulated radiotherapy (SW-IMRT) in head and neck cancer: Clinical validation according to the model-based approach

Author

Christianen, Miranda E.M.C., van der Schaaf, Arjen, van der Laan, Hans Paul, Verdonck-de Leeuw, Irma M., Doornaert, Patricia, Chouvalova, Olga, Steenbakkers, Roel J.H.M., Leemans, Charles René, Oosting, Sjoukje F., van der Laan, Bernard F.A.M., Roodenburg, Jan L.N., Slotman, Ben J., Bijl, Hendrik P., and Langendijk, Johannes A.

Published
2016
Full Text
View/download PDF

31. Development of a multivariable normal tissue complication probability (NTCP) model for tube feeding dependence after curative radiotherapy/chemo-radiotherapy in head and neck cancer

Author

Wopken, Kim, Bijl, Hendrik P., van der Schaaf, Arjen, van der Laan, Hans Paul, Chouvalova, Olga, Steenbakkers, Roel J.H.M., Doornaert, Patricia, Slotman, Ben J., Oosting, Sjoukje F., Christianen, Miranda E.M.C., van der Laan, Bernard F.A.M., Roodenburg, Jan L.N., René Leemans, C., Verdonck-de Leeuw, Irma M., and Langendijk, Johannes A.

Published
2014
Full Text
View/download PDF

32. A Randomized Ph2 Study of MEDI0680 in Combination With Durvalumab vs. Nivolumab Monotherapy in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Author

Voss, Martin H, Azad, Arun A, Hansen, Aaron R, Gray, Jhanelle E, Welsh, Sarah J, Song, Xuyang, Kuziora, Michael, Meinecke, Lina, Blando, Jorge, Achour, Ikbel, Wang, Yi, Walcott, Farzana, Oosting, Sjoukje F, and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Abstract

BACKGROUND: MEDI0680 is a humanized anti-programmed cell death-1 (PD-1) antibody and durvalumab is an anti-PD-L1 antibody. Combining treatment using these antibodies may improve efficacy versus blockade of PD-1 alone. This phase 2 study evaluated antitumor activity and safety of MEDI0680 plus durvalumab versus nivolumab monotherapy in immunotherapy naïve patients with advanced clear cell renal cell carcinoma who received at least one prior line of anti-angiogenic therapy. METHODS: Patients received either MEDI0680 (20 mg/kg) with durvalumab (750 mg) or nivolumab (240 mg), all IV Q2W. The primary endpoint was investigator-assessed objective response rate (ORR). Secondary endpoints included best overall response, progression-free survival (PFS), safety, overall survival (OS), and immunogenicity. Exploratory endpoints included changes in circulating tumor DNA (ctDNA), baseline tumor mutational burden (TMB), and tumor-infiltrated immune cell profiles. RESULTS: Sixty-three patients were randomized (combination, n = 42; nivolumab, n = 21). ORR was 16.7% (7/42; 95% CI, 7.0-31.4) with combination treatment and 23.8% (5/21; 95% CI, 8.2- 47.2) with nivolumab. Median PFS was 3.6 months in both arms; median OS was not reached in either arm. Due to AEs, 23.8% of patients discontinued MEDI0680 and durvalumab and 14.3% of patients discontinued nivolumab. In the combination arm, reduction in ctDNA fraction was associated with longer PFS. ctDNA mutational analysis did not demonstrate an association with response in either arm. Tumor-infiltrated immune profiles showed an association between immune cell activation and response in the combination arm. CONCLUSIONS: MEDI0680 combined with durvalumab was safe and tolerable; however, it did not improve efficacy versus nivolumab monotherapy.

Published
2022

33. Needs and preferences of patients with head and neck cancer in integrated care

Author

van Overveld, L.F.J., Takes, R.P., Turan, A.S., Braspenning, J.C.C., Smeele, L.E., Merkx, M.A.W., Hermens, R.P.M.G., Baatenburg de Jong, Rob J., de Boer, Jan P., Brouns, John J.A., Bun, Rolf J., van Dijk, Boukje A.C., Dortmans, Judith A.W.F., van Es, Robert J.J., Hoebers, Frank J.P., Kropveld, Arvid, Langendijk, Johannes A., Langeveld, Ton P.M., Oosting, Sjoukje F., Verschuur, Hendrik P., de Visscher, Jan G.A.M., and van Weert, Stijn

Published
2018
Full Text
View/download PDF

34. Androgen deprivation therapy for androgen receptor‐positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands

Author

Boon, Eline, van Boxtel, Wim, Buter, Jan, Baatenburg de Jong, Robert J., van Es, Robert J. J., Bel, Miranda, Fiets, Edward, Oosting, Sjoukje F., Slingerland, Marije, Hoeben, Ann, Tesselaar, Margot E. T., Jonker, Marianne A., Flucke, Uta E., van der Graaf, Winette T. A., and van Herpen, Carla M. L.

Published
2018
Full Text
View/download PDF

35. Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours

Author

Oosting, Sjoukje F, van der Veldt, Astrid A M, Fehrmann, Rudolf S N, GeurtsvanKessel, Corine H, van Binnendijk, Rob S, Dingemans, Anne-Marie C, Smit, Egbert F, Hiltermann, T Jeroen N, den Hartog, Gerco, Jalving, Mathilda, Westphal, Tatjana T, Bhattacharya, Arkajyoti, de Wilt, Faye, Boerma, Annemarie, van Zijl, Lisanne, Rimmelzwaan, Guus F, Kvistborg, Pia, van Els, Cecile A C M, Rots, Nynke Y, van Baarle, Debbie, Haanen, John B A G, and de Vries, Elisabeth G E

Published
2022
Full Text
View/download PDF

36. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma

Author

Nakauma-González, J. Alberto, Rijnders, Maud, van Riet, Job, van der Heijden, Michiel S., Voortman, Jens, Cuppen, Edwin, Mehra, Niven, van Wilpe, Sandra, Oosting, Sjoukje F., Rijstenberg, L. Lucia, Westgeest, Hans M., Zwarthoff, Ellen C., de Wit, Ronald, van der Veldt, Astrid A.M., van de Werken, Harmen J.G., Lolkema, Martijn P.J., and Boormans, Joost L.

Published
2022
Full Text
View/download PDF

37. Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults

Author

Boon, Eline, van der Graaf, Winette T. A., Gelderblom, Hans, Tesselaar, Margot E. T., van Es, Robert J. J., Oosting, Sjoukje F., de Bree, Remco, van Meerten, Esther, Hoeben, Ann, Smeele, Ludi E., Willems, Stefan M., Witjes, Max J. H., Buter, Jan, Baatenburg de Jong, Robert J., Flucke, Uta E., Peer, Petronella G. M., Bovée, Judith V. M. G., and Van Herpen, Carla M. L.

Published
2017
Full Text
View/download PDF

39. Methylated Cell-Free DNA Sequencing (MeD-seq) of LpnPI Digested Fragments to Identify Early Progression in Metastatic Renal Cell Carcinoma Patients on Watchful Waiting.

Author

Bos, Manouk K., Verhoeff, Sarah R., Oosting, Sjoukje F., Menke-van der Houven van Oordt, Willemien C., Boers, Ruben G., Boers, Joachim B., Gribnau, Joost, Martens, John W. M., Sleijfer, Stefan, van Herpen, Carla M. L., and Wilting, Saskia M.

Subjects
RENAL cell carcinoma, DISEASE progression, SEQUENCE analysis, METASTASIS, HEALTH outcome assessment, DNA methylation, RISK assessment, COMPARATIVE studies, DESCRIPTIVE statistics, RESEARCH funding, TUMOR markers, EXTRACELLULAR space, PROGRESSION-free survival, NUCLEIC acids, EARLY diagnosis, PROPORTIONAL hazards models, EVALUATION
Abstract

Simple Summary: A subset of patients with an intermediate risk for renal cell carcinoma have an indolent disease course. For these patients, the initiation of treatment for metastatic disease can be safely delayed by entering a watchful waiting period. At present, we are not able to identify those patients with indolent disease and the minor group of patients with rapidly progressive disease requiring earlier initiation of systemic treatment. In this study, we investigate whether cell-free DNA (cfDNA) can be used as a blood-based biomarker to identify those patients with rapid progression. Methylated cfDNA profiles were used as a proxy for tumor load in blood. cfDNA methylation patterns were associated with the time to radiological progression, but not with the watchful waiting time. The results of this study do not provide definite proof that cfDNA methylation patterns are associated with WW time. According to the current guidelines, watchful waiting (WW) is a feasible option for patients with good or intermediate prognosis renal-cell carcinoma (RCC). However, some patients rapidly progress during WW, requiring the initiation of treatment. Here, we explore whether we can identify those patients using circulating cell-free DNA (cfDNA) methylation. We first defined a panel of RCC-specific circulating methylation markers by intersecting differentially methylated regions from a publicly available dataset with known RCC methylation markers from the literature. The resulting RCC-specific methylation marker panel of 22 markers was subsequently evaluated for an association with rapid progression by methylated DNA sequencing (MeD-seq) in serum from 10 HBDs and 34 RCC patients with a good or intermediate prognosis starting WW in the IMPACT-RCC study. Patients with an elevated RCC-specific methylation score compared to HBDs had a shorter progression-free survival (PFS, p = 0.018), but not a shorter WW-time (p = 0.15). Cox proportional hazards regression showed that only the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria were significantly associated with WW time (HR 2.01, p = 0.01), whereas only our RCC-specific methylation score (HR 4.45, p = 0.02) was significantly associated with PFS. The results of this study suggest that cfDNA methylation is predictive of PFS but not WW. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

41. 89Zr-DFO-durvalumab PET/CT prior to durvalumab treatment in patients with recurrent or metastatic head and neck cancer.

Author

Verhoeff, Sarah R., van de Donk, Pim P., Aarntzen, Erik H. J. G., Oosting, Sjoukje F., Brouwers, Adrienne H., Miedema, Iris H. C., Voortman, Jens, Menke-van der Houven van Oordt, Willemien C., Boellaard, Ronald, Vriens, Dennis, Slingerland, Marije, Hermsen, Rick, van Engen-van Grunsven, Ilse, Heskamp, Sandra, and van Herpen, Carla M. L.

Published
2022
Full Text
View/download PDF

45. From presentation to paper: Gender disparities in oncological research

Author

Dijksterhuis Willemieke PM, Stroes Charlotte I, Tan Wan-Ling, Ithimakin Suthinee, Valles Antonio, van Oijen Martijn GH, Barriuso Jorge, Oosting Sjoukje F, Kolarevic Ivankovic Daniela, Furness Andrew JS, Božović-Spasojević Ivana, Gomez-Roca Carlos, and van Laarhoven Hannekw WM

Subjects
research, sex, Congresses as topic, medical oncology
Abstract

Gender disparities in scientific publications have been identified in oncological research. Oral research presentations at major conferences enhance visibility of presenters. The share of women presenting at such podia is unknown. We aim to identify gender‐based differences in contributions to presentations at two major oncological conferences. Abstracts presented at plenary sessions of the American Society of Clinical Oncology (ASCO) Annual Meetings and European Society for Medical Oncology (ESMO) Congresses were collected. Trend analyses were used to analyze female contribution over time. The association between presenter's sex, study outcome (positive/negative) and journals' impact factors (IFs) of subsequently published papers was assessed using Chi‐square and Mann–WhitneyUtests. Of 166 consecutive abstracts presented at ASCO in 2011–2018 (n= 34) and ESMO in 2008–2018 (n= 132), 21% had female presenters, all originating from Northern America (n= 17) or Europe (n= 18). The distribution of presenter's sex was similar over time (p= 0.70). Of 2,425 contributing authors to these presented abstracts, 28% were women. The proportion of female abstract authors increased over time (ppp= 0.82). Median journals' IFs were lower in papers with a female first author (p&nbsp

Published
2020

47. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands

Author

Boon, Eline, Bel, Miranda, van Boxtel, Wim, van der Graaf, Winette T. A., van Es, Robert J. J., Eerenstein, Simone E. J., Baatenburg de Jong, Robert J., van den Brekel, Michiel W. M., van der Velden, Lilly‐Ann, Witjes, Max J. H., Hoeben, Ann, Willems, Stefan M., Bloemena, Elisabeth, Smit, Laura A., Oosting, Sjoukje F., Jonker, Marianne A., Flucke, Uta E., van Herpen, Carla M. L., Guided Treatment in Optimal Selected Cancer Patients (GUTS), ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Damage and Repair in Cancer Development and Cancer Treatment (DARE), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), MKA AMC (OII, ACTA), MKA Vumc (OII, ACTA), and Otorhinolaryngology and Head and Neck Surgery

Subjects
Adult, Male, DATABASE, Receptor, ErbB-2, receptor, Receptor, ErbB-2/metabolism, Receptors, Androgen/metabolism, THERAPY, survival, Disease-Free Survival, ErbB-2, Recurrence, ErbB‐2, Journal Article, FAILURE, Humans, Salivary Ducts, Neoplasm Metastasis, Carcinoma/pathology, salivary duct carcinoma, Aged, Netherlands, Aged, 80 and over, OUTCOMES, Carcinoma, Palliative Care, ANDROGEN RECEPTOR, Salivary Ducts/pathology, Chemoradiotherapy, Adjuvant, Middle Aged, Prognosis, Salivary Gland Neoplasms, Survival Rate, androgen receptors, Receptors, Androgen, Lymphatic Metastasis, immunohistochemistry, Female, in situ hybridization, fluorescence, Factor Analysis, Statistical, Salivary Gland Neoplasms/pathology, Cancer Epidemiology
Abstract

Salivary duct carcinoma (SDC) is a subtype of salivary gland cancer with a dismal prognosis and a need for better prognostication and novel treatments. The aim of this national cohort study was to investigate clinical outcome, prognostic factors, androgen receptor (AR) and human epidermal growth factor receptor 2 (HER2) expression. SDC patients diagnosed between 1990 and 2014 were identified by the Nationwide Network and Registry of Histo‐ and Cytopathology in the Netherlands (PALGA). Subsequently, medical records were evaluated and pathological diagnoses reviewed. Data were analyzed for overall survival (OS), disease‐free survival (DFS), distant metastasis‐free survival (DMFS) and prognostic factors. AR was evaluated by immunohistochemistry (IHC), HER2 by IHC and fluorescent in‐situ hybridization. A total of 177 patients were included. The median age was 65 years, 75% were male. At diagnosis, 68% presented with lymph node metastases and 6% with distant metastases. Median OS, DFS and DMFS were 51, 23 and 26 months, respectively. In patients presenting without distant metastases, the absolute number of positive lymph nodes was associated with poor OS and DMFS in a multivariable analysis. AR and HER2 were positive in 161/168 (96%) and 44/153 (29%) tumors, respectively, and were not prognostic factors. SDC has a dismal prognosis with primary lymph node involvement in the majority of patients. The absolute number of lymph node metastases was found to be the only prognostic factor for DMFS and OS. AR expression and—to a lesser extent—HER2 expression hold promise for systemic treatment in the metastatic and eventually adjuvant setting., What's new? Salivary duct carcinoma (SDC) is a rare and often fatal malignancy. Little is known about associations between its pathological features and clinical outcome. In this study, clinicopathological factors were analyzed for 177 patients diagnosed with SDC in The Netherlands between 1990 and 2014. The data show that median overall survival (OS) and distant metastasis‐free survival (DMFS) were 51 and 26 months, respectively. At diagnosis, 68% of patients presented with lymph node metastases. Lymph node positivity was associated with poor OS and poor DMFS. The absolute number of metastatic lymph nodes was the only significant prognostic factor for survival in a multivariate analysis. Androgen receptor and human epidermal growth factor 2 (HER2) were positive in 96% and 29%, respectively and were not a prognostic factor.

Published
2018

48. Comparative biodistribution analysis across four different Zr-monoclonal antibody tracers-The first step towards an imaging warehouse

Author

Bensch, Frederike, Smeenk, Michaël M, van Es, Suzanne C, de Jong, Johan R, Schröder, Carolina P, Oosting, Sjoukje F, Lub-de Hooge, Marjolijn N, Menke-van der Houven van Oordt, C Willemien, Brouwers, Adrienne H, Boellaard, Ronald, de Vries, Elisabeth G E, Guided Treatment in Optimal Selected Cancer Patients (GUTS), and ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE)

Abstract

Rationale: Knowledge on monoclonal antibody biodistribution in healthy tissues in humans can support clinical drug development. Molecular imaging with positron emission tomography (PET) can yield information in this setting. However, recent imaging studies have analyzed the behavior of single antibodies only, neglecting comparison across different antibodies. Methods: We compared the distribution of four 89Zr-labeled antibodies in healthy tissue in a retrospective analysis based on the recently published harmonization protocol for 89Zr-tracers and our delineation protocol. Results: The biodistribution patterns of 89Zr-lumretuzumab, 89Zr-MMOT0530A, 89Zr-bevacizumab and 89Zr-trastuzumab on day 4 after tracer injection were largely similar. The highest tracer concentration was seen in healthy liver, spleen, kidney and intestines. About one-third of the injected tracer dose was found in the circulation, up to 15% in the liver and only 4% in the spleen and kidney. Lower tracer concentration was seen in bone marrow, lung, compact bone, muscle, fat and the brain. Despite low tracer accumulation per gram of tissue, large-volume tissues, especially fat, can influence overall distribution: On average, 5-7% of the injected tracer dose accumulated in fat, with a peak of 19% in a patient with morbid obesity. Conclusion: The similar biodistribution of the four antibodies is probably based on their similar molecular structure, binding characteristics and similar metabolic pathways. These data provide a basis for a prospectively growing, online accessible warehouse of molecular imaging data, which enables researchers to increase and exchange knowledge on whole body drug distribution and potentially supports drug development decisions.

Published
2018

49. A patient with metastatic melanoma presenting with gastrointestinal perforation after dacarbazine infusion: a case report

Author

Hospers Geke AP, Peters Frans TM, Oosting Sjoukje F, and Mulder Nanno H

Subjects
Medicine
Abstract

Abstract Introduction We report a rare case of gastrointestinal perforation following dacarbazine infusion for metastatic melanoma. The condition is attributed to a responding malignant melanoma in the gastrointestinal tract. Case presentation A 52-year-old Caucasian man presented with abdominal pain and distension, malaise, night sweats, dysphagia and early satiety. A computed tomography scan showed massive ascites, lymphadenopathy and liver lesions suspect for metastases. An upper gastrointestinal endoscopy was performed and revealed multiple dark lesions of 5 mm to 10 mm in his stomach and duodenum. When his skin was re-examined, an irregular pigmented lesion over the left clavicle measuring 15 mm × 8 mm with partial depigmentation was found. Histological examination of a duodenal lesion was consistent with a diagnosis of metastatic melanoma. The patient deteriorated and his level of lactate dehydrogenase rapidly increased. The patient was started on systemic treatment with dacarbazine 800 mg/m2 every three weeks and he was discharged one day after the first dose. On the sixth day he was readmitted with severe abdominal pain. A chest X-ray showed the presence of free intraperitoneal air that was consistent with gastrointestinal perforation. His lactate dehydrogenase level had fallen from 6969U/L to 1827U/L, supporting the conclusion that the response of gastrointestinal metastases to dacarbazine had resulted in the perforation of the patient's bowel wall. A laparotomy was discussed with the patient and his family but he decided to go home with symptomatic treatment. He died 11 days later. Conclusion Melanoma can originate in, as well as metastasize to, the gastrointestinal tract. Gastrointestinal perforations due to responding tumors are a well-known complication of systemic treatment of gastrointestinal lymphomas. However, as the response rate of metastatic melanoma to dacarbazine is only 10% to 20%, and responses are usually only partial, perforation due to treatment response in metastatic melanoma is rare. Medical oncologists should be aware of the risk of bowel perforation after starting cytotoxic chemotherapy on patients with gastrointestinal metastases.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results